Iain Gilbert Sharecast News
31 Jan, 2025 09:32

Alliance Pharma FY profits seen in line with expectations

dl alliance pharma plc aim health care healthcare pharmaceuticals and biotechnology pharmaceuticals logo 20230112
Alliance PharmaSharecast graphic / Josh White

Alliance Pharma

62.50p

17:00 27/02/25
1.13%
0.70p

International healthcare firm Alliance Pharma said on Friday that FY24 group profits would be in line with expectations despite a modest downturn in revenues.

FTSE AIM 100

3,410.68

16:54 27/02/25
n/a
n/a

FTSE AIM 50

3,730.71

16:54 27/02/25
n/a
n/a

FTSE AIM All-Share

707.72

16:54 27/02/25
n/a
n/a

Pharmaceuticals & Biotechnology

22,414.59

17:14 27/02/25
0.25%
56.96

Alliance Pharma said it had delivered group see-through revenues of £180.3m in FY24, down 1% year-on-year, but noted that while revenues declined in some of its brands, it had delivered a "strong performance" in Kelo-Cote, MacuShield, Hydromol and Forceval.

Chief executive Nick Sedgwick said: " I am pleased that performance in 2024 is in-line with expectations. Whilst we have much to do as we work on our transformation plans, I am confident that our strong portfolio of clinically differentiated brands will deliver predictable organic revenue growth over the mid-long term."

As of 0930 GMT, Alliance Pharma shares were up 0.33% at 61.40p.

Reporting by Iain Gilbert at Sharecast.com

contador